PulseAI wins FDA clearance for smartwatch ECG software
Belfast's PulseAI received FDA 510(k) clearance for software that reads ECG recordings from smartwatches and other devices. Full analysis is cleared for Apple Watch Series 6 and standard ECGs.
Pulse, covering wearables and health sensors
, 3 min read
K254226FDA 510(k) number for PulseAPI SmartWatch
What to know
- The FDA cleared PulseAI's PulseAPI SmartWatch software on October 27, 2026, under 510(k) K254226.
- Full rhythm analysis is cleared for standard ECGs and Apple Watch Series 6; Samsung, Fitbit, Withings and AliveCor devices get atrial fibrillation and sinus rhythm only.
- It is a prescription device, used under a physician's care, not a consumer app feature.
PulseAI, a Belfast medical software company, has received US Food and Drug Administration clearance for software that interprets electrocardiogram (ECG) recordings taken on smartwatches and other ECG devices. The FDA's letter, dated October 27, 2026, clears the product, called PulseAPI SmartWatch, under 510(k) number K254226. The company announced the clearance on November 5.
The software does not run on the watch. Recordings are sent to PulseAI's cloud service, which returns a rhythm interpretation to the connected app, according to Business News Today.
What the FDA cleared
The FDA filing describes a software library that assesses heart rhythm in ECGs from adults, used when prescribed by or under the care of a physician. It is a Class II device, and its predicate (the device it was compared with for clearance) is AliveCor's KardiaAI. Our explainer on what FDA clearance means covers how the 510(k) route works.
The scope depends on the device that made the recording:
- Full analysis is cleared for standard wet-electrode ECGs and for the Apple Watch Series 6. For Apple Watch Series 6 recordings, the summary lists outputs for sinus rhythm, atrial fibrillation (AFib), slow and fast heart rates, extra beats known as premature ventricular contractions (PVCs), and beat detection.
- Reduced analysis, limited to sinus rhythm and AFib on a single lead, is cleared for Samsung Galaxy Watch, Fitbit Sense, Withings ScanWatch and AliveCor's KardiaMobile devices.
The filing says the software is not for people with pacemakers or implanted defibrillators and is not an alarm system. It does not list other Apple Watch models.
The study behind the pitch
PulseAI's marketing leans on a study in the journal Heart Rhythm, which is separate from the FDA filing; the 510(k) summary reports no accuracy figures from it. According to Securities.io, the study recorded Apple Watch ECGs from 296 adults admitted to an Irish teaching hospital for heart rhythm procedures, and compared Apple's built-in algorithm with PulseAI's on the same recordings.
Under the study's main "pragmatic" scoring, which counts inconclusive results as misses, Apple's algorithm detected AFib with 78.1% sensitivity and 81.0% specificity, both reports say. PulseAI's scored 98.4% and 96.1%. The share of first recordings marked inconclusive fell from 17.6% to 1.4%, Securities.io reports, which the company describes as a 92% reduction. PulseAI funded the study, and authors disclosed ties to the company.
Business News Today notes the study does not show fewer strokes, hospital stays or lower costs. Sensitivity and specificity also depend heavily on who is tested: this group was hospital patients, about a fifth of whom had AFib, not the general public wearing watches.
Who is behind it
PulseAI raised a seed round in January 2026 led by Innovation Ulster, Ulster University's investment arm, with the Mortara Group taking part. The amount was not disclosed. Founder and CEO Alan Kennedy said the aim is "bringing this capability into the devices and platforms in use by millions," according to Securities.io. The company has not named app or clinic partners or prices.
Why it matters
Smartwatch ECGs often come back "inconclusive," leaving doctors to read the trace themselves. Cleared third-party software that interprets recordings from several brands gives clinics and health apps another way to handle them, though the full feature set is cleared for only one Apple Watch model. Watchmakers are also adding their own cleared heart features, such as Apple Watch hypertension alerts, and Google has published research on smartwatch blood pressure screening. For background on what watch sensors can and cannot measure, see our explainer on heart rate variability.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- 510(k) K254226: PulseAPI SmartWatch (letter and summary), U.S. Food and Drug Administration, October 27, 2026
- Belfast's PulseAI gains 510(k) clearance for wearable ECG AI, Securities.io, November 5, 2026
- PulseAI wins FDA clearance for smartwatch ECG analysis after study shows 92% fewer inconclusive results, Business News Today, November 6, 2026
Heart health techFDA and health regulationWearablesDigital health and AI in care
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.